Phase 1 clinical study to assess effect of cudetaxestat on pharmacokinetics of two approved therapies for idiopathic pulmonary fibrosis (IPF) Company on track to initiate planned phase 2 clinical ...
DUBLIN--(BUSINESS WIRE)--The "CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...
DelveInsight's PDE4 Inhibitor Market Report Reveals Significant Growth Through 2034, Led by Arcutis Biotherapeutics, Pfizer, Shionogi, Palisade Bio, UNION Therapeutics, Amgen, and Chiesi Farmaceutici ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results